HomeClinics HomeAbout ClinicsAll ClinicsHot TopicsAdvancesSpecial OffersCME
Logo
Search for

Volume 18, Issue 2, Pages 325-337 (April 2009)


View previous. 13 of 16 View next.

Transplantation for Cholangiocarcinoma: When and for Whom?

David J. Rea, MDa, Charles B. Rosen, MDaCorresponding Author Informationemail address, David M. Nagorney, MDb, Julie K. Heimbach, MDa, Gregory J. Gores, MDc

Liver transplantation for cholangiocarcinoma has historically been maligned. Because of a high recurrence rate and poor patient survival, the disease has been viewed as an absolute contraindication to transplantation. Based on good results using neoadjuvant and palliative radiation, a protocol for liver transplantation in selected patients with unresectable hilar cholangiocarcinoma was developed in 1993. Neoadjuvant radiation is followed by operative staging to rule out patients with lymph node metastases before liver transplantation. This approach has achieved results superior to standard surgical therapy, with 72% 5-year survival for patients with unresectable disease.

a Division of Transplantation Surgery, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA

b Division of Gastrointestinal and General Surgery, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA

c Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA

Corresponding Author InformationCorresponding author.

PII: S1055-3207(08)00129-4

doi:10.1016/j.soc.2008.12.008


View previous. 13 of 16 View next.